Reported 2 days ago
Merck & Co., Inc. (MRK) continues to demonstrate a robust dividend history, rewarding shareholders with rising dividends for 14 years. Despite a slight dip in revenue to $15.5 billion in the first quarter of 2025, Merck exceeded analyst expectations, driven by strong sales of its products, including KEYTRUDA. The company offers a quarterly dividend of $0.81 per share, yielding 4.05%. Its commitment to innovation is evident with recent regulatory approvals for new treatments and vaccines, positioning it among the best pharma dividend stocks to buy in 2025.
Source: YAHOO